Pharmacokinetic/Pharmacodynamic Modeling of the PDE4 Inhibitor TAK‐648 in Type 2 Diabetes: Early Translational Approaches for Human Dose Prediction

TAK‐648 is a PDE4 inhibitor with demonstrated preclinical antidiabetic properties. Our objective was to develop a translational pharmacokinetic/pharmacodynamic (PK/PD) model for human type 2 diabetes (T2D) dose prediction using HbA(1c) results from a db/db mouse study. Estimated parameters in combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Plock, N, Vollert, S, Mayer, M, Hanauer, G, Lahu, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421726/
https://www.ncbi.nlm.nih.gov/pubmed/28088839
http://dx.doi.org/10.1111/cts.12436

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5421726/
https://www.ncbi.nlm.nih.gov/pubmed/28088839
http://dx.doi.org/10.1111/cts.12436

Ejemplares similares